Eligo Bioscience

Eligobiotics is a new generation of antimicrobials that can be programmed to target bacteria based on their genome. Eligobiotics therefore provide a new approach to explore, understand and control bacterial ecosystems both in human and animals. They can notably be used to selectively eradicate harmful pathogens from the microbiome while sparing beneficial ones.
Company Growth (employees)
Paris, FR
Size (employees)
15 (est)+67%
Eligo Bioscience was founded in 2014 and is headquartered in Paris, FR

Eligo Bioscience Office Locations

Eligo Bioscience has an office in Paris
Paris, FR (HQ)
18 Rue du Dr Roux

Eligo Bioscience Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$22.2 m

Latest funding size

$18 m

Time since last funding

about 2 months


Eligo Bioscience's latest funding round in September 2017 was reported to be $18 m. In total, Eligo Bioscience has raised $22.2 m

Eligo Bioscience's Web-traffic and Trends

Eligo Bioscience Online and Social Media Presence

Eligo Bioscience Company Life and Culture

You may also be interested in